Original Text: |
    Patients should be considered platinum-refractory (progression while on a prior platinum chemotherapy) or resistant (persistence or recurrence within 6 months after a prior platinum chemotherapy) and be deemed unlikely to have significant benefit from any standard therapies by the treating investigator
Disease/Condition: none
Procedure: none
Drug: none
Biomarker: none
Computable Rule: |
    "Platinum Refractory OR Resistant AND Unlikely To Benefit" is True
